Video

Dr David Eagle: Progress in Hematology/Oncology Is Not Without Its Difficulties

Author(s):

For all the success the hematology/oncology space has seen over the past 20-plus years, difficult discussions now focus on paying for that care, explained David A. Eagle, MD, New York Cancer & Blood Specialists.

David A. Eagle, MD, chair of legislative affairs and patient advocacy at New York Cancer & Blood Specialists, explains how even progress has its drawbacks, as for all the success the hematology/oncology space has seen over the past 20-plus years, difficult discussions now focus on paying for that care.

Transcript

In the past 2-plus decades, what have been some of the biggest advancements in hematology/oncology?

The biggest advantages have clearly been on the scientific level: immunotherapy, targeted therapy. It begins with oncogenes, where we finally figured out, really, what makes a cancer a cancer. That’s clearly been the biggest progress in oncology. The problem is, as we talked about earlier, that that’s creating a natural tension between what we can do for patients and how we actually pay for that care.

Related Videos
Toby Maher, MD, PhD, professor of clinical medicine, Keck School of Medicine at USC
Nini Wu, MD, Navista
Fred Locke, MD, Moffitt Cancer Center and Research Institute
Dr Emma Achola-Kothari
Matthew Viggiano, MD, internal medicine resident, Temple University Hospital
Krunal Patel, MD, pulmonary and critical care fellow, Temple University Hospital
M. Bradley Drummond, MD, MHS, professor of medicine, University of North Carolina at Chapel Hill
Dr Margrit Wiesendanger
John Barkett, MBA
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo